BridgeBio Pharma (NASDAQ:BBIO) has priced its public offering of ~8.8M common shares at $17.00/share, for gross proceeds of ~$150M.
Underwriters’ over-allotment is an additional ~1.3M shares.
Closing date is March 10.
All of the shares in the offering to be sold by BridgeBio.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Previously (March 6): BridgeBio Pharma announces $150M public offering
Source: Seeking Alpha